Retrospective analysis of clinical outcomes of patients with COVID-19 depending on receiving antihypertensive, lipid-lowering and antihypertensive therapy

Background. The main factors that increase the risk of cardiovascular accidents and mortality among patients with COVID-19 include hyperglycemia, arterial hypertension and dyslipidemia. Therefore, all patients with COVID-19 and metabolic syndrome should receive antihypertensive (AHT), hypolipidemic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tatiana Yu. Demidova, Kristina G. Lobanova, Sergey N. Perekhodov, Michail B. Antsiferov, Olga S. Oynotkinova
Formato:	article
Lenguaje:	RU
Publicado:	"Consilium Medicum" Publishing house 2021
Materias:	type 2 diabetes mellitus hypertension antihypertensive drugs hypoglycemic drugs covid-19 favipiravirum Medicine R
Acceso en línea:	https://doaj.org/article/a324d85d2b694f45bd8dce55506f770a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a324d85d2b694f45bd8dce55506f770a
record_format	dspace
spelling	oai:doaj.org-article:a324d85d2b694f45bd8dce55506f770a2021-12-01T12:22:36ZRetrospective analysis of clinical outcomes of patients with COVID-19 depending on receiving antihypertensive, lipid-lowering and antihypertensive therapy0040-36602309-534210.26442/00403660.2021.10.201072https://doaj.org/article/a324d85d2b694f45bd8dce55506f770a2021-10-01T00:00:00Zhttps://ter-arkhiv.ru/0040-3660/article/viewFile/86950/65135https://doaj.org/toc/0040-3660https://doaj.org/toc/2309-5342Background. The main factors that increase the risk of cardiovascular accidents and mortality among patients with COVID-19 include hyperglycemia, arterial hypertension and dyslipidemia. Therefore, all patients with COVID-19 and metabolic syndrome should receive antihypertensive (AHT), hypolipidemic (GLT) and hypoglycemic therapy (GGT). Currently, there is a limited number of studies regarding the effectiveness and safety of this therapy in patients with COVID-19. Aim. Evaluate the clinical outcomes of patients with COVID-19, depending on the recipient of AHT, GLT and GGT. Materials and methods. A retrospective analysis of the clinical outcomes "discharged/died" of 1753 patients with COVID-19 was carried out depending on the received AHT, GLT and GGT. Results. A significant reduction in the risk of mortality among patients with COVID-19 was observed during therapy with angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers ACE inhibitors/ARBs (OR 0.39, 95% CI 0.210.72; p0.05) and b-adrenergic blockers b-AB (OR 0.53, 95% CI 0.281; p0.05). At the same time, against the background of therapy with ACE inhibitors/ARBs and b-ABs, the chance of mortality decreased more significantly among patients with type 2 diabetes mellitus (T2DM) compared with patients without T2DM. Diuretic therapy was associated with a 3-fold increase in the chances of death: OR 3.33, 95% CI 1.884.79; p0.05. Statin therapy did not affect clinical outcomes in COVID-19 patients. On the background of therapy with oral hypoglycemic drugs, the risk of mortality decreased 5-fold (OR 0.19, 95% CI 0.070.54; p0.05). Against the background of insulin therapy, there was an increase in mortality risk by 2.8 times (OR 2.81, 95% CI 1.55.29; p0.05). Conclusion. A significant reduction in mortality among patients with COVID-19 was observed during therapy with ACEI/ARB, b-AB, and oral hypoglycemic therapy. Increased risk of death was associated with insulin therapy and diuretic therapy.Tatiana Yu. DemidovaKristina G. LobanovaSergey N. PerekhodovMichail B. AntsiferovOlga S. Oynotkinova"Consilium Medicum" Publishing housearticletype 2 diabetes mellitushypertensionantihypertensive drugshypoglycemic drugscovid-19favipiravirumMedicineRRUТерапевтический архив, Vol 93, Iss 10, Pp 1193-1202 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	type 2 diabetes mellitus hypertension antihypertensive drugs hypoglycemic drugs covid-19 favipiravirum Medicine R
spellingShingle	type 2 diabetes mellitus hypertension antihypertensive drugs hypoglycemic drugs covid-19 favipiravirum Medicine R Tatiana Yu. Demidova Kristina G. Lobanova Sergey N. Perekhodov Michail B. Antsiferov Olga S. Oynotkinova Retrospective analysis of clinical outcomes of patients with COVID-19 depending on receiving antihypertensive, lipid-lowering and antihypertensive therapy
description	Background. The main factors that increase the risk of cardiovascular accidents and mortality among patients with COVID-19 include hyperglycemia, arterial hypertension and dyslipidemia. Therefore, all patients with COVID-19 and metabolic syndrome should receive antihypertensive (AHT), hypolipidemic (GLT) and hypoglycemic therapy (GGT). Currently, there is a limited number of studies regarding the effectiveness and safety of this therapy in patients with COVID-19. Aim. Evaluate the clinical outcomes of patients with COVID-19, depending on the recipient of AHT, GLT and GGT. Materials and methods. A retrospective analysis of the clinical outcomes "discharged/died" of 1753 patients with COVID-19 was carried out depending on the received AHT, GLT and GGT. Results. A significant reduction in the risk of mortality among patients with COVID-19 was observed during therapy with angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers ACE inhibitors/ARBs (OR 0.39, 95% CI 0.210.72; p0.05) and b-adrenergic blockers b-AB (OR 0.53, 95% CI 0.281; p0.05). At the same time, against the background of therapy with ACE inhibitors/ARBs and b-ABs, the chance of mortality decreased more significantly among patients with type 2 diabetes mellitus (T2DM) compared with patients without T2DM. Diuretic therapy was associated with a 3-fold increase in the chances of death: OR 3.33, 95% CI 1.884.79; p0.05. Statin therapy did not affect clinical outcomes in COVID-19 patients. On the background of therapy with oral hypoglycemic drugs, the risk of mortality decreased 5-fold (OR 0.19, 95% CI 0.070.54; p0.05). Against the background of insulin therapy, there was an increase in mortality risk by 2.8 times (OR 2.81, 95% CI 1.55.29; p0.05). Conclusion. A significant reduction in mortality among patients with COVID-19 was observed during therapy with ACEI/ARB, b-AB, and oral hypoglycemic therapy. Increased risk of death was associated with insulin therapy and diuretic therapy.
format	article
author	Tatiana Yu. Demidova Kristina G. Lobanova Sergey N. Perekhodov Michail B. Antsiferov Olga S. Oynotkinova
author_facet	Tatiana Yu. Demidova Kristina G. Lobanova Sergey N. Perekhodov Michail B. Antsiferov Olga S. Oynotkinova
author_sort	Tatiana Yu. Demidova
title	Retrospective analysis of clinical outcomes of patients with COVID-19 depending on receiving antihypertensive, lipid-lowering and antihypertensive therapy
title_short	Retrospective analysis of clinical outcomes of patients with COVID-19 depending on receiving antihypertensive, lipid-lowering and antihypertensive therapy
title_full	Retrospective analysis of clinical outcomes of patients with COVID-19 depending on receiving antihypertensive, lipid-lowering and antihypertensive therapy
title_fullStr	Retrospective analysis of clinical outcomes of patients with COVID-19 depending on receiving antihypertensive, lipid-lowering and antihypertensive therapy
title_full_unstemmed	Retrospective analysis of clinical outcomes of patients with COVID-19 depending on receiving antihypertensive, lipid-lowering and antihypertensive therapy
title_sort	retrospective analysis of clinical outcomes of patients with covid-19 depending on receiving antihypertensive, lipid-lowering and antihypertensive therapy
publisher	"Consilium Medicum" Publishing house
publishDate	2021
url	https://doaj.org/article/a324d85d2b694f45bd8dce55506f770a
work_keys_str_mv	AT tatianayudemidova retrospectiveanalysisofclinicaloutcomesofpatientswithcovid19dependingonreceivingantihypertensivelipidloweringandantihypertensivetherapy AT kristinaglobanova retrospectiveanalysisofclinicaloutcomesofpatientswithcovid19dependingonreceivingantihypertensivelipidloweringandantihypertensivetherapy AT sergeynperekhodov retrospectiveanalysisofclinicaloutcomesofpatientswithcovid19dependingonreceivingantihypertensivelipidloweringandantihypertensivetherapy AT michailbantsiferov retrospectiveanalysisofclinicaloutcomesofpatientswithcovid19dependingonreceivingantihypertensivelipidloweringandantihypertensivetherapy AT olgasoynotkinova retrospectiveanalysisofclinicaloutcomesofpatientswithcovid19dependingonreceivingantihypertensivelipidloweringandantihypertensivetherapy
_version_	1718405191159513088

Retrospective analysis of clinical outcomes of patients with COVID-19 depending on receiving antihypertensive, lipid-lowering and antihypertensive therapy

Ejemplares similares